Written by David Lim

***excerpt***

“By rejecting Massachusetts’ 1115 waiver request to establish a closed Medicaid formulary and still receive 23.1% mandatory manufacturer rebates, the administration is protecting patients’ access to critical treatments and upholding the bargain that Congress struck with states and manufacturers in the 1990s,” Greenleaf said in a statement.

***end excerpt***

***

[/el-text]

View full article here